Le Lézard
Classified in: Health
Subject: MRR

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research


PORTLAND, Ore., April 16, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Emphysema Treatment Market by Treatment Type (Medication, Oxygen Therapy, and Surgery), Type (Centriacinar, Panacinar, and Others), End User (Hospitals, Homecare, Specialty Centres, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the emphysema treatment market was valued at $6.3 billion in 2022, and is estimated to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Allied_Market_Research_Logo

Request Sample of the Report on Emphysema Treatment Market Forecast - https://www.alliedmarketresearch.com/request-sample/A14372 

Prime Determinants of Growth 

The emphysema treatment market has experienced significant growth owing to rise in prevalence of emphysema cases globally. Furthermore, rise in number of smokers has contributed in the increasing prevalence of emphysema. In addition, Asia-Pacific is expected to present significant opportunities for growth owing to rise in awareness programs for emphysema, increasing diagnosis and increase in investments for well-developed healthcare infrastructure.

Report coverage & details 

Report Coverage 

Details 

Forecast Period 

2022?2032 

Base Year 

2022

Market Size in 2022 

$6.30 Billion 

Market Size in 2032 

$8.73 Billion 

CAGR 

3.3 %

No. of Pages in Report 

321

Segments covered 

Treatment Type, Type, End User, and Region 

Regional scope 

North America, Europe, Asia-Pacific and LAMEA 

Country scope 

U.S., Canada, Mexico; France, Germany, Italy, Spain, UK, Rest of Europe

China, Japan, India, South Korea, Australia, Rest of Asia-Pacific

Brazil, South Africa, Saudi Arabia, and rest of LAMEA 

Drivers 

Increase in prevalence of emphysema cases


Surge in number of smokers globally


Increase in air pollution contributing to emphysema

Opportunity 

Side effects associated with medications

Restraint 

High cost of treatment

2023 Recession Impact Analysis 

The global recession has significant impact on emphysema treatment market. The economic instability has had adverse effects on fresh investments and funding allocated to R&D activities for developing new & advanced emphysema treatment options. In addition, financial strain has led to reductions in budgets for hospital management.  

However, the market for emphysema treatment is expected to recover owing to rise in prevalence of emphysema. 

Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/A14372 

The medication segment to maintain its leadership status throughout the forecast period 

Depending on treatment type, the medication segment held the highest market share in 2022, accounting for almost three-fourths of the market revenue, owing to high adoption of the medications such as bronchodilators and steroids for treatment of emphysema. In addition, easy availability and cost-effectivity of the medication contribute toward high adoption of the medications.  

The centriacinar segment to maintain its leadership status throughout the forecast period 

By type, the centriacinar segment held the highest market share in 2022, accounting for almost half of market revenue, owing to high prevalence of centriacinar emphysema. In addition, rise in number of smokers globally has contributed significantly in the rising prevalence of centriacinar emphysema. 

The homecare segment to maintain its leadership status throughout the forecast period 

On the basis of end user, the homecare segment held the highest market share in 2022, accounting for more than two-fifths of the emphysema treatment market revenue, owing to rising trend toward home healthcare. In addition, the development of portable oxygen therapy has contributed toward the growth of the segment. 

For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/A14372 

North America to maintain its leadership status throughout the forecast period 

Region wise, North America held the highest market share in 2022, accounting for two-fifths of emphysema treatment market revenue. This is attributed to surge in R&D activities, well-developed healthcare infrastructure, and rise in prevalence of emphysema.  

However, Asia-Pacific is expected to register a noteworthy CAGR during the forecast period, owing to decreasing air quality index, initiatives for early diagnosis, and increasing healthcare investments. 

Leading Market Players

The report provides a detailed analysis of these key players in the emphysema treatment market. These players have adopted different strategies such as acquisition, agreement, investment, product launch, product approval, and clinical trials to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.  

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
Web: https://www.alliedmarketresearch.com  
Follow Us on: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg


These press releases may also interest you

at 14:08
Life Time today announced the appointment of James LaValle, clinical pharmacist, C.C.N.M.T. as Chief Science Officer. LaValle will spearhead the development and implementation of scientific initiatives and strategic relationships to support MIORA,...

at 14:01
Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, announced today the expansion of patent protection in Europe for its NIMBUS®...

at 13:50
The push for a transformative U.S.-India partnership in newborn screening (NBS) sets the stage for a seismic shift in tackling rare diseases, spotlighting the need to prepare for the digital AI revolution in global healthcare. Advocates are rallying...

at 13:39
Today, the U.S. Food and Drug Administration announced it will host a listening session in June as part of its broader work to optimize the use of, and processes for, advisory committees. This virtual public meeting will focus on the composition of...

at 13:35
The hormonal changes that women experience throughout their lives put them at increased risk for serious or chronic health conditions like diabetes, stroke, obesity, and even breast cancer. Fortunately, managing...

at 13:31
Healthcare providers are a vital resource for autistic adolescents and their families as they prepare for the transition to adulthood, which may include learning to drive, according to a new study from researchers at Children's Hospital of...



News published on and distributed by: